Dosage for Kenalog 10 Injection is individualized based on the condition and patient response. Kenalog 10 Injection may interact with aminoglutethimide, birth control pills, hormone replacement therapy, blood thinners, cyclosporine, digoxin, insulin or diabetes medications you take by mouth, isoniazid, rifampin, seizure medication, antibiotics, aspirin, or other NSAIDs (nonsteroidal anti-inflammatory drugs). Tell your doctor all medications you are taking. Kenalog 10 Injection should be used during pregnancy only if prescribed. This medication may be harmful to a fetus. Infants born to mothers who have received corticosteroids during pregnancy should be observed for signs of hypoadrenalism. This medication can pass into breast milk and may harm a nursing baby. Consult your doctor before breastfeeding.
Treatment is difficult. Due to the intensity of the itch patients often go from doctor to doctor looking for relief. No one treatment is always effective and several treatments may need to be tried. Initial treatment is often potent prescription steroid creams . If these help, a milder cream can be used for longer-term control. Antihistamine creams (Zonalon, Pramoxine) or pills (Atarax, Periactin) are often added for additional relief. Intralesional steroid injections , anti-depressant pills, and non-prescription capsaicin cream helps many of those not improved with the usual treatment.
The adverse effects of corticosteroids in pediatric patients are similar to those in adults (see ADVERSE REACTIONS ). Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of infection, psychosocial disturbances, thromboembolism , peptic ulcers, cataracts, and osteoporosis. Pediatric patients who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of HPA axis suppression (ie, cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The linear growth of pediatric patients treated with corticosteroids should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of treatment alternatives. In order to minimize the potential growth effects of corticosteroids, pediatric patients should be titrated to the lowest effective dose.